JMP Group JMP
-
Anthera Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
… LLC, Research Division Christopher Mortko Edward A. Tenthoff - Piper Jaffray Companies, Research Division Heather Behanna - JMP Securities LLC, Research Division Presentation Operator Good day, ladies and gentlemen, and thank you for standing by, and …
-
MicroStrategy ([[MSTR]] -1.7%) trades lower in response to a downgrade to Market Perform from JMP . The downgrade comes 3 weeks after shares were clobbered thanks to a giant Q1 miss headlined by a 24% ...
MicroStrategy ( MSTR -1.7% ) trades lower in response to a downgrade to Market Perform from JMP . The downgrade comes 3 weeks after shares were clobbered thanks to a giant Q1 miss headlined by a 24% Y/Y drop in license revenue …
-
Cavium ([[CAVM]] -2.7%) slides thanks to a downgrade to Market Perform from JMP . The network processor vendor has been rallying since delivering a Q1 beat and better-than-feared Q2 guidance on April ...
Cavium ( CAVM -2.7% ) slides thanks to a downgrade to Market Perform from JMP . The network processor vendor has been rallying since delivering a Q1 beat and better-than-feared Q2 guidance on April 30. Post your comment!
-
IPO Preview: Marketo
… May 6, 2013 Manager, Joint Managers : Goldman, Sachs; Credit Suisse Co Managers: UBS; Canaccord Genuity; Raymond James; JMP Securities SUMMARY MKTO provides a cloud-based marketing software platform, similar to Eloqua, which was recently acquired …
-
IPO Preview: Tableau Software
… Manager,Joint Managers:Goldman, Sachs; Morgan Stanley Co Managers:Credit Suisse;J.P. Morgan; UBS; BMO Capital; JMP Securities SUMMARY Data believes it is "democratizing" the use of business analytics software. On a year-over-year basis …
-
Cyclacel Pharmaceuticals (CYCC) announces an offering to sell shares, however the size and terms were not disclosed. The company also expects to grant the underwriters a 30-day option to cover ...
… the underwriters a 30-day option to cover overallotments, if any. All of the shares in this offering are to be sold by the company. JMP Securities LLC is acting as the sole book-running manager. Shares -7.5% AH. Post your comment!
-
Ares' CEO Discusses Q1 2013 Results - Earnings Call Transcript
… John Bartling - Chief Executive Officer Bruce Cohen - Chief Operation Officer Analysts Joel Houck - Wells Fargo Steve Delaney - JMP Securities Jade Rahmani - KBW Presentation Operator Good morning. Welcome to Ares Commercial Real Estate Corporation's Conference …
-
Esperion Therapeutics, a biopharmaceutical company focused on the development of therapies for the treatment of high cholesterol and other cardiometabolic risk factors, files for a $70M IPO. The ...
… risk factors, files for a $70M IPO . The company plans to list on the Nasdaq Global Market under the ticker "ESPR." The offering is being managed through Credit Suisse, Citigroup, JMP Securities, and Stifel Nicolaus. Post your comment!
-
Epizyme, a clinical stage biopharmaceutical company focused on therapeutics for patients with genetically defined cancers, files for a 4.285M share IPO. The company hasn't set an expected price range ...
… price range as of yet, but plans to list on the The Nasdaq Global Market under the symbol "EPZM." The offering will be made through Citigroup, Cowen, Leerink Swann, JMP Securities, and Wedbush PacGrow Life Sciences. Post your comment!
-
For those who've noticed American Capital Mortgage's ([[MTGE]] -3%) allocation to non-agency MBS has declined from a typical 30% to 20%, co-CIO Jeff Winkler (he's in charge of non-agencies, Gary Kain ...
… declined from a typical 30% to 20%, co-CIO Jeff Winkler (he's in charge of non-agencies, Gary Kain does agencies) says ( JMP presentation ) don't forget Q1's capital raise. The firm rapidly deployed the new funds into agency paper and will over …